SGTX - Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer

Sigilon Therapeutics (SGTX) announces the appointment of Philip Ashton-Rickardt as the company's chief scientific officer ((CSO)).Most recently, Ashton-Rickardt served as Senior Vice President for Immunology at AZTherapies.At AZTherapies, he was responsible for preclinical development of cell therapies, biologic and small molecule platform technologies to treat neurodegenerative diseases."The breadth and depth of Philip's experience will be instrumental in helping us leverage the modularity of our Shielded Living Therapeutics platform as we advance multiple programs," CEO Rogerio Vivaldi said.

For further details see:

Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer